Skip to main content

Month: March 2022

ELEKTRA SELECTS ATHENA BITCOIN GLOBAL (OTC:ABIT) TO PROCESS BITCOIN PAYMENTS USING THE LIGHTNING NETWORK

Chicago/Mexico City, March 31, 2022 (GLOBE NEWSWIRE) — (via Blockchain Wire) Today, Athena Bitcoin Global announces that Elektra, part of Grupo Salinas, has appointed Athena to process Bitcoin payments using the Lightning Network. Athena Bitcoin is providing the fiat crypto bridge, assuring processing and liquidity in compliance with national regulatory requirements, making Lightning Network payments possible.   Elektra has more than 1,300 points of sale in Mexico and in Latin America. In December 2021, Elektra became the first Mexican retailer to accept bitcoin. All goods and services available online and in-store can now be paid instantly with the Lightning Network.   Athena helps clients cross the “last mile” that connects crypto commerce to local currencies by providing custom solutions and 24-hour bank settlement....

Continue reading

Philips enables seamless echocardiography workflows with the launch of Ultrasound Workspace at ACC 2022

Clinicians reviewing ultrasound scanMarch 31, 2022Industry leading vendor-neutral solution for automated 2D and 3D quantification for browser-accessible echocardiography analysis and reporting New solution provides seamless diagnostic workflows and identical applications, on and off the ultrasound cart Artificial intelligence (AI) driven automated image analysis and quantification features help increase efficiency and diagnostic qualityAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Ultrasound Workspace [OLK1] at the American College of Cardiology’s Annual Scientific Session & Expo (ACC 2022). Philips Ultrasound Workspace [1] is an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed...

Continue reading

Registration of new shares in Talenom Oyj in accordance with the terms of the Option Scheme

Talenom Plc, Stock Exchange Release 31 March at 15:00 EET Registration of new shares in Talenom Oyj in accordance with the terms of the Option Scheme The 130,000 new shares subscribed for in line with Talenom Oyj’s 2019 terms and conditions for option rights are estimated to be registered in the Trade Register on 6 April 2022. The total subscription price, EUR 380,900.00, will be recognised in full in the company’s reserve for invested unrestricted equity. After the registration of the new shares the total number of shares in Talenom Oyj is 44,461,055 shares. The new shares will carry shareholder rights as of their registration day. The new shares are estimated to be admitted for public trade on the official list of Nasdaq Helsinki Ltd on 7 April 2022. TALENOM PLCBOARD OF DIRECTORS Further information:Otto-Pekka HuhtalaCEO, Talenom...

Continue reading

Businesses aren’t getting the message: new report finds brands are leaving customers frustrated by failing to reply

CX-report-2022–PR Businesses aren’t getting the message: new report finds brands are leaving customers frustrated by failing to reply  Over half of consumers express frustration, shop elsewhere, when their responses to brand messages go unanswered STOCKHOLM, Sweden, and ATLANTA — March 31, 2022 — Consumers are being unintentionally ignored by businesses, according to a new study of almost 3,000 consumers across 15 countries, commissioned by Sinch (Sinch AB (publ) – XSTO: SINCH). The study found 89% of people want to initiate and reply to two-way conversations with businesses, via multiple mobile and social channels. However, over half (53%) recalled a frustrating time when they discovered they could not reply to a mobile message sent from a business, for example to ask a question, receive an update or complete an action,...

Continue reading

Wee-Cig, EZ365 CEO Launches On the Block Podcast Series with Matrix Mortgage Global

Dynamic Bi-weekly Podcast of Leading Experts will Explore Disruptive Potential Of Digital Assets & Blockchain Technology in the Global Mortgage Industry LAS VEGAS, CA, March 31, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Wee-Cig International Corporation (OTCMarkets: WCIG), a company focused on identifying and growing top tech companies in emerging markets, today announced that its CEO and Founder of operating subsidiary dba, “EZ365”, Russell Korus, will co-host a bi-weekly podcast series, On the Block, alongside Shawn Allen, CEO and Broker of Record, Matrix Mortgage Global. The On the Block podcast aims to foster early education and engagement across the multi-trillion-dollar mortgage sector, ensuring the industry’s future readiness to leverage digital assets including NFTs. Each podcast will share valuable information for...

Continue reading

Sono Motors Technology Used for Munich’s First Solar Bus — MVG to Put Solar Bus Trailer Into Operation

Sono Motors Technology Used for Munich’s First Solar Bus — MVG to Put Solar Bus Trailer Into Operation Sono Motors Technology Used for Munich’s First Solar Bus — MVG to Put Solar Bus Trailer Into OperationSono Motors Innovative Solar Technology for Buses Is Used in Real Conditions in Munich for the First Time Solar Bus Trailer for the Münchner Verkehrsgesellschaft (Munich Transport Company, MVG) to Reduce Local CO2 Emissions by Over 6.5 Metric Tonnes per Year per Vehicle, Thus Supporting the City of Munich’s Clean Air Targets Further Benefits Include Fuel Savings of up to 2,500 Liters of Diesel per Year, Stabilization of Energy Supply and Extension of the 24V Battery Life, as Well as Reduced Maintenance Costs 20 Semi-Flexible Special Solar Panels Provide a Total Output of Over 2,000 Watts Sono Motors and the MVG Present the Novel Solar...

Continue reading

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.S. commercial launch of XACIATO expected in 4Q-2022 Initiated communication with the FDA to support a full IDE review for Ovaprene with plans to start the pivotal Phase 3 clinical study in 2022 $51.7 million in cash and cash equivalents at December 31, 2021 Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2021 and provided a company update. “We made significant progress across the portfolio during 2021 and into the first quarter of 2022, most notably...

Continue reading

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2021. These results are included in the Company’s Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: “Reiterating my comments from our shareholders meeting in December, I am proud of our team and their accomplishments during 2021. It was a challenging year for many companies, particularly in biotech and drug development. Our experienced new team coalesced in identifying and addressing pertinent issues with a prescience...

Continue reading

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today provided a business update and announced its financial results for the year ended December 31, 2021. “I’m very pleased to report that we have undergone a 12-month period of incredible productivity here at PDS Biotech,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of the Company. “We’ve made significant clinical progress on our lead oncology candidate, PDS0101, and presented at leading...

Continue reading

Unicycive Announces Full Year 2021 Financial Results and Provides Business Update

On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022 Plans to initiate Phase 1 study for UNI-494 in second half of 2022 LOS ALTOS, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2021 and provided a business update. “The considerable progress we made throughout 2021 puts us in a strong position to execute on our strategy to advance our clinical development programs to address two important renal diseases where current treatment options are suboptimal,” said Shalabh Gupta, M.D., Chief Executive Officer. “Central to our progress was the confirmatory...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.